Day: November 15, 2021

Posted on

COMMENT | Let the Fourth Estate do its job without fear or favour

Published by
Malaysiakini (English)

COMMENT | Although the political culture of Malaysia isn’t like the US, the media should still be regarded as the Fourth Estate. Journalists do play a role and function in holding politicians to account and thereby complement the check-and-balance dynamics in our political system. As such, the contribution of journalists in highlighting current issues, including abuse of power and illegal or unconstitutional acts, are to be accorded their due respect. Therefore, Minderjeet Kaur (Free Malaysia Today journalist) was only doing her job as a component of the Fourth Estate. This is why for politici… Continue reading “COMMENT | Let the Fourth Estate do its job without fear or favour”

Posted on

YOURSAY | The hypocrisy is palpable

Published by
Malaysiakini (English)

YOURSAY | ‘Muhyiddin, you can spin it any way you want.’ Muhyiddin positions PN as the moral choice, fires coup and 1MDB salvos at Umno Siva1967: Bersatu president Muhyiddin Yassin, you can spin it any way you want. The fact of the matter is you and your Bersatu partners along with Azmin Ali and his cohorts are the ones who started this irresponsible act of overthrowing the government. You went back to the very “enemy” that you swore to overthrow and gave them an opening to walk back into the corridors of power, knowing full well that it is in Umno’s nature to wait for the opportunity to strik… Continue reading “YOURSAY | The hypocrisy is palpable”

Posted on

International Handball Federation partners with Sportradar Integrity Services

Sportradar’s proven fraud detection services to help protect the integrity of global handball competition

BASEL, Switzerland & ST GALLEN, Switzerland, Nov. 15, 2021 (GLOBE NEWSWIRE) — The International Handball Federation (IHF) and Sportradar Integrity Services – a global supplier of sport integrity solutions and partner to over 100 sports federations and leagues – have today entered a multi-year agreement for the monitoring of global handball events. Sportradar Integrity Services is a unit of Sportradar (NASDAQ: SRAD) (“Sportradar” or “the Company”), the leading global sports technology company.

Under the agreement, Sportradar Integrity Services will draw upon its substantial experience and expertise – having monitored global betting markets for more than 16 years – to provide bet monitoring via its Universal Fraud Detection System (UFDS) for IHF events, including both the men’s and women’s World, Junior and Youth World Championships, as well as the IHF Super Globe. Sportradar considers bet monitoring essential to every sport and believes that the service should be available to help protect all levels of competition.

The UFDS is an advanced and proven bet monitoring system that has been independently assessed and verified by recognized experts in the field of sports betting and integrity. Betting patterns are analysed for abnormalities by a global team of qualified integrity experts, and any suspicious matches are subsequently reported to partners, allowing critical visibility into worldwide match-fixing. Sportradar Integrity Services have detected over 6,500 suspicious matches during the past 16 years with more than 750 of these taking place in 2021 alone.

IHF President Dr Hassan Moustafa said: “We recognize the modern-day integrity threats that face global sport, and handball is no exception. The IHF makes it a top priority to have robust measures in place to help safeguard the integrity of our major events, not just at men’s and women’s senior level, but also at youth and junior level. Sportradar have a proven track record in the field of sports integrity, and the depth of their bet monitoring capabilities will help to support our overall integrity programme in the years ahead.”

Sportradar Integrity Services Managing Director Andreas Krannich added: “We are delighted to partner with IHF to help support their integrity programme with our UFDS bet monitoring solution. We have witnessed rising integrity issues in handball over the past five years, and so we credit the vigilance shown by IHF in adding to the integrity provisions surrounding their events. At Sportradar, we are fully committed to assisting our partners’ integrity efforts and look forward to working together with the IHF to support the journey of global handball in the coming years.”

ABOUT SPORTRADAR INTEGRITY SERVICES:
Sportradar Integrity Services is a leading supplier of monitoring, intelligence, education, and consultancy solutions for sports organisations, state authorities, and law enforcement agencies to support them in the fight against match-fixing and corruption. Trusted and relied on by more than 100 sports’ governing bodies and leagues around the world and staffed with executives who have implemented integrity policies for the world’s largest sports bodies and leagues, we are firmly established as the unrivalled market leader in the field of sporting integrity.

ABOUT SPORTRADAR:
Sportradar is the leading global sports technology company creating immersive experiences for sports fans and bettors. Established in 2001, the company is well-positioned at the intersection of the sports, media and betting industries, providing sports federations, news media, consumer platforms and sports betting operators with a range of solutions to help grow their business. Sportradar employs more than 2,300 full time employees across 19 countries around the world. It is our commitment to excellent service, quality and reliability that makes us the trusted partner of more than 1,600 customers in over 120 countries and an official partner of the NBA, NHL, MLB, NASCAR, FIFA, UEFA, ICC, and ITF. We cover more than 750,000 events annually across 83 sports. With deep industry relationships, Sportradar is not just redefining the sports fan experience; it also safeguards the sports themselves through its Integrity Services division and advocacy for an integrity-driven environment for all involved.

For more information about Sportradar, please visit www.sportradar.com

Source: Sportradar Group AG

Press Contacts:
Sportradar
Sandra Lee
comms@sportradar.com

Investor Relations Contacts:
Ankit Hira or Ed Yuen
Solebury Trout for Sportradar
investor.relations@sportradar.com

Posted on

Innovation Zed Announce 2022 Launch of InsulCheck DOSE Add-on Technology for Insulin Pens

InsulCheck DOSE by Innovation Zed

InsulCheck DOSE by Innovation Zed

DUBLIN, Nov. 15, 2021 (GLOBE NEWSWIRE) — Innovation Zed, developer of novel diabetes management technologies (the InsulCheck range), headquartered at NovaUCD, at University College Dublin, Ireland are delighted to announce today the arrival of the much anticipated InsulCheck DOSE technology that will be coming to market in 2022.

“It is with great excitement that we announce the arrival of our InsulCheck DOSE by Innovation Zed. As the third generation product of the InsulCheck family, this technology has been a dream of our company from its very inception and this product is the culmination of over a decade of work to support multiple daily injection (MDI) pen users. We understood the difficult challenges presented by various injection pens and in particular the difficulties in working on a technology to reliably and accurately support low-cost disposable pens. This is the reason we at Innovation Zed took an incremental approach to developing the InsulCheck DOSE product.” – said Dr Dean Minnock, CEO at Innovation Zed. “We have taken a unique approach in developing this technology by working closely with users, caregivers, software developers, medical device specialists and previous generations of InsulCheck products to design and develop a product that bolsters and supports the needs of all stakeholders” – he continued.

Innovation Zed has collaborated with SHL Medical in the development of InsulCheck DOSE. SHL Medical is a world-leading provider of drug delivery solutions and also offers design-to-build and contract manufacturing services for various medical products through its subsidiary, SHL Technologies.

What is InsulCheck DOSE?

InsulCheck DOSE is a single unit add-on device for pen injectors that automatically captures dose value dialled, injection event time stamp, temperature and mounting/unmounting events. Through Bluetooth® Low Energy (BLE) technology, InsulCheck DOSE transmits these data points to a paired companion software platform in real time for inclusion in diabetes management therapy.

“InsulCheck DOSE technology supports MDI users by enhancing their traditional injection pen and transforming it into a smart pen that can optimise their treatment and reduce the stresses caused by MDI therapy. Through this technology we are enabling every MDI user to make their existing injection pen a smart pen without having to compromise or change from their existing HMO or health service provider” – said Dr Minnock.

InsulCheck DOSE Features

The technology utilises a multi-sensor approach to accurately detect and register the actual dosage dialled and provide an injection event time stamp to log the event. The incorporated temperature sensors constantly monitor the ambient temperature of the area surrounding the injection pen, providing safety notifications to the user if the surrounding temperature may affect the drug housed inside the pen. Using an OLED display, InsulCheck DOSE provides visual information and feedback to the user, helping improve best practice procedures. A rechargeable lithium battery powers the DOSE device and is capable of operating well over 1 week at a time between charges. As a BLE enabled product, all data captured by InsulCheck DOSE is transferred in real time to a paired mobile application. If the user does not wish or is unable to remain connected with a companion software platform, InsulCheck DOSE has built-in memory to store over 40 days’ worth of injection history at a time. Through modification of the sleeve component and firmware refinement, InsulCheck DOSE can become applicable to all injection pens for various drug treatments. At launch, it will support a range of reusable and disposable injection pens on the insulin market from Novo Nordisk, Lilly and Sanofi.

“Our ability to learn, adapt and improve our technology is one of the key aspects of InsulCheck DOSE and one that separates us greatly from our competitors. The future-proof design of InsulCheck DOSE means that it can be adapted to support the various pen mechanisms in use today, whilst maintaining accuracy and reliability for the patient. Among the numerous unique features of this product is the built in Firmware Over The Air (FOTA) capability which allows continuous optimisation of the device’s firmware even when deployed in the field. That future-proofing allows InsulCheck DOSE to adapt to physical injection pen variations from the pen manufacturers and improve on device performance ‘on the go’ from real world user behaviours” – said Dr Minnock.

Value Proposition

The InsulCheck DOSE device helps patients, automatically track their daily injection and monitor treatment adherence. The intended use of InsulCheck DOSE is as a supporting component in a management ecosystem for therapy optimisation, remote monitoring and enhanced connected care. Dr Minnock explained, “InsulCheck DOSE is a disruptive technology that will revolutionise an entire market and change the lives of millions of MDI users worldwide. Innovation Zed have entered into discussions with market leaders in the diabetes management sector with the intention of finding a strategic global partner in taking this InsulCheck DOSE technology to the market. InsulCheck DOSE is an attractive offering to any organisation working in this space as it can significantly enhance their existing offering to become more competitive and command new growth and additional market share.”

Conclusion

InsulCheck DOSE enters production at the end of Q2 2022 and will be available as an FDA registered and CE marked product. Manufacturing of InsulCheck DOSE will be handled by Innovation Zed’s existing manufacturing partner SHL Technologies, a subsidiary of SHL Medical. If you wish to understand InsulCheck DOSE or any of our technology offerings in greater detail, please feel free to visit our website or reach out to us directly.

Editors Notes

Innovation Zed designs connected health solutions that support drug adherence and Condition Management. As technologies continue to evolve, it opens new and exciting possibilities for connected healthcare to deliver increased freedom and control to patients. That is why Innovation Zed is actively developing and researching new methods to improve drug adherence and optimise treatment to enable more personalised condition management. www.innovationzed.com.

Media Contact

Dean Minnock, CEO, Innovation Zed
deanm@innovationzed.com

______________

The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Innovation Zed is under license. Other trademarks and trade names are those of their respective owners.

Related Images

Image 1: InsulCheck DOSE by Innovation Zed

InsulCheck DOSE is an add-on device for injection pens that captures various injection events, including dose dialled, and transmits data to a companion app via Bluetooth®

This content was issued through the press release distribution service at Newswire.com.

Attachment

.

Posted on

Claims that Pasar Payang traders died of COVID-19 not true – JKNT

KUALA TERENGGANU, Nov 15 — The Terengganu Health Department (JKNT) has denied claims which went viral on social media recently that several traders at Pasar Besar Kedai Payang here had died due to COVID-19.

Its director Datuk Dr Kasemani Embong said that there was an outbreak among traders at the market but no deaths were reported.

“From Oct 31 until Saturday (Nov 13), some 36 out of 1,000 traders at the market have contracted COVID-19.

“All of them have been isolated and given treatment. Two of them were admitted to the Sultanah Nur Zahirah Hospital and have been discharged. All close contacts have been identified and asked to undergo quarantine,” she said in a statement today.

Therefore, Dr Kasemani urged the public not to spread fake news to avoid confusion among the community, adding that JKNT would take the necessary measures to contain the COVID-19 transmission.

Source: BERNAMA News Agency

Posted on

Pak Lah is fine, rumours on death untrue

KUALA LUMPUR, Nov 15 — The Office of Tun Abdullah Ahmad Badawi today announced that the former prime minister is in good health with his family.

In a statement today, the office refuted the viral posts on Facebook belonging to ‘Mohd Hasni Izuwan’ and Saifulzaman Mahmood’ claiming that the country’s fifth prime minister, who is fondly known as Pak Lah, had died.

“The office views seriously the rumours and will take legal action against those who spread fake news,” it said.

The office also urged the public to verify the authenticity of such news with the relevant authorities before spreading information that can lead to confusion.

Meanwhile, according to Housing and Local Government Minister Datuk Seri Reezal Merican Naina Merican, Pak Lah’s wife, Tun Jeanne Abdullah is also in good health.

“I just spoke to her on the phone, they are currently on a vacation in the country,” he said in a post on his official Facebook page.

Reezal Merican also called on all Malaysians to stop spreading fake news and pray for Abdullah and Jeanne’s good health and long life.

Source: BERNAMA News Agency

Posted on

Celltrion secures CHMP positive opinion for regdanvimab (CT-P59) over COVID-19 treatment

KUALA LUMPUR, Nov 15 — Celltrion Group has announced the European Medicine’s Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) issued a positive scientific opinion recommending marketing authorisation for regdanvimab (CT-P59).

regdanvimab (CT-P59) is a monoclonal antibody treatment for adults with COVID-19 that do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

The CHMP positive opinion is a scientific recommendation to the European Commission (EC), which authorises marketing approval in the European Union, according to a statement.

“We have accumulated the safety and efficacy data of regdanvimab in the treatment of patients infected with COVID-19 and its associated variant strains, including the more virulent Delta variant,” said Head of Medical and Marketing Division at Celltrion Healthcare, Dr HoUng Kim, Ph.D.

“At Celltrion, we are proud to play our part in tackling the unprecedented global threat of COVID-19 and believe regdanvimab offers an important addition to the treatment arsenal.”

The positive CHMP opinion was supported by data from the global Phase III clinical trial in which Celltrion enrolled more than 1,315 people to evaluate the efficacy and safety of regdanvimab in 13 countries including the US, Spain, and Romania.

Data showed regdanvimab significantly reduced the risk of COVID-19 related hospitalisation or death by 72 per cent for patients at high-risk of progressing to severe COVID-19.

Rolling review of regdanvimab had been initiated by the EMA in February this year and the announcement of the CHMP positive opinion for regdanvimab follows the submission of a marketing authorisation application (MAA) to the EMA seeking approval of regdanvimab in October.

Source: BERNAMA News Agency